Albert Dobi
Overview
Explore the profile of Albert Dobi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sinopole K, Babcock K, Dobi A, Petrovics G
Biomedicines
. 2024 Nov;
12(11).
PMID: 39595156
Purpose Of Review: This review aims to describe the role of limbic system-associated membrane protein (LSAMP) in normal- and pathophysiology, and its potential implications in oncogenesis. We have summarized research...
2.
Diossy M, Tisza V, Li H, Sahgal P, Zhou J, Sztupinszki Z, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):208.
PMID: 39294262
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain...
3.
Patkar S, Harmon S, Sesterhenn I, Lis R, Merino M, Young D, et al.
J Pathol Inform
. 2024 Jul;
15:100381.
PMID: 38953042
The Gleason score is an important predictor of prognosis in prostate cancer. However, its subjective nature can result in over- or under-grading. Our objective was to train an artificial intelligence...
4.
Szallasi Z, Diossy M, Tisza V, Li H, Sahgal P, Zhou J, et al.
Res Sq
. 2024 Apr;
PMID: 38645014
We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that...
5.
Ghandadi M, Dobi A, V Malhotra S
Biochim Biophys Acta Rev Cancer
. 2024 Apr;
1879(3):189100.
PMID: 38604268
RIO (right open reading frame) family of kinases including RIOK1, RIOK2 and RIOK3 are known for their role in the ribosomal biogenesis. Dysfunction of RIO kinases have been implicated in...
6.
Chand N, Tekumalla P, Rosenberg M, Dobi A, Ali A, Miller G, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398103
Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific...
7.
Bataba E, Babcock K, Isensee K, Eldhose B, Kohaar I, Chesnut G, et al.
Curr Oncol Rep
. 2024 Jan;
26(2):175-180.
PMID: 38265515
Purpose Of Review: Prostate cancer is the most frequently diagnosed non-cutaneous malignancy of men in the USA; notably, the incidence is higher among men of African, followed by European and...
8.
Bowling G, Swargaloganathan P, Heintz C, Madan R, Eldhose B, Dobi A, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835597
Background: Poly ADP-ribose polymerase inhibitors (PARPis) are an important class of therapeutics for metastatic castration-resistant prostate cancer (mCRPC). Unlike hormone-based treatments for mCRPC, PARPis are not without drug-related hematological adverse...
9.
Duncan A, Nousome D, Ricks R, Kuo H, Ravindranath L, Dobi A, et al.
Biomedicines
. 2023 May;
11(5).
PMID: 37239075
Growing evidence indicates the involvement of a genetic component in prostate cancer (CaP) susceptibility and clinical severity. Studies have reported the role of germline mutations and single nucleotide polymorphisms (SNPs)...
10.
Schafer C, Young D, Singh H, Jayakrishnan R, Banerjee S, Song Y, et al.
J Immunol Methods
. 2023 May;
518:113493.
PMID: 37196930
Background: Aberrant ETV1 overexpression arising from gene rearrangements or mutations occur frequently in prostate cancer, round cell sarcomas, gastrointestinal stromal tumors, gliomas, and other malignancies. The absence of specific monoclonal...